Project description:Two human primary fibroblast cell lines indicated in the file names were either treated with carfilzomib (C) at the concentrations near the IC50 of proteasome activity (10nM) for 24h, or with DMSO (D) as a control, in biological duplicates (numbers 1-2).
Project description:Human skin fibroblast cell line, Susa was treated with DMSO (control) or with fraglide-1 (5H4PB) for 24h subjected to RNA extraction for RNA-seq.
Project description:Cell lines indicated in the file names were either treated with carfilzomib (C) at concentrations near the IC50 of proteasome activity in each cell line for 24h, or with DMSO (D) as a control, in biological duplicates.
Project description:The NPC cell line C666_1 is known to be infected with Epstein Barr virus (EBV), and to have high expression of SSTR2A. The cell line was treated with PENN221 (an SSTR2A targeted drug conjugate) , Belinostat (a histone deacetylase inhibitor), DMSO (negative control) or left untreated (negative control). Both PENN221 and Belinstat resulted in increased cell death of the cell line. Treated samples were sequenced at 24h and 72h post treatment.
Project description:Investigation of the time dependent effect of Cpd1 (small molecule interactor) on the proteome composition of melanoma WM3734 line by label-free quantification using mass spectrometry. The goal was to identify which protein abundances are increased upon treatment with Cpd1. Melanoma cell line WM3734 was treated with Cpd1 and with the control DMSO. Samples were taken at two time points, 24h and 72h.
Project description:Data independent acquisition (DIA) mass spectrometry was used to study the potent inhibitors for cancer derived fibroblast cell line, CT5-3hTERT. The fibroblast spheroids were treated with 21 different tumor inhibitors to compare their effect in proteome in comparison to treated with DMSO.
Project description:To generate drug signatures in human WM35 melanoma cell line. WM35 cell line was plated at 4 x 105 cells/mL overnight and treated with ciclopirox or crizotinib at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.
Project description:To generate drug signatures in human WM35 melanoma cell line. WM35 cell line was plated at 4 x 105 cells/mL overnight and treated with trifluridine or lactimidomycin at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.
